Key Details
Price
$48.25Last Dividend
$2.04Annual Revenue
$50.28 BAnnual EPS
$2.33Annual ROE
7.18%Beta
0.07Events Calendar
Next earnings date:
Jan 30, 2025Recent quarterly earnings:
Oct 25, 2024Recent annual earnings:
Feb 01, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
May 09, 2024Next split:
N/ARecent split:
Sept 30, 2013Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SNY has started a phase III trial for its 21-valent pneumococcal conjugate vaccine, which aims to treat invasive pneumococcal disease in young children. This study focuses on infants and toddlers.
Sanofi has started a phase 3 program for PCV21 and is also increasing its partnership with SK bioscience to develop new types of pneumococcal conjugate vaccines.
Jean-Paul Kress will join Sanofi's Board of Directors on January 1, 2025. He is taking the place of Gilles Schnepp, who has chosen to step down from the Board at the end of 2024. The Board is happy to have Kress as an independent director.
A new experimental drug developed in partnership with Sanofi and Teva has successfully achieved its main objectives in a mid-stage trial for treating Ulcerative colitis and Crohn's disease.
Sanofi (SNY) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to additional price growth in the short term.
Shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY), which are traded in the U.S., rose sharply on Tuesday after both companies announced encouraging results from their research on a treatment for ulcerative colitis (UC) and Crohn's disease.
On Tuesday, Teva Pharmaceutical Industries Ltd. and Sanofi SA announced that their Phase 2b RELIEVE UCCD study achieved its main goals for patients with ulcerative colitis and Crohn's disease.
Teva Pharmaceutical Industries from Israel and the French company Sanofi announced that a study on a medication for ulcerative colitis and Crohn's disease achieved its main objectives.
Duvakitug has shown promising phase 2b results, indicating it could be a leading treatment for ulcerative colitis and Crohn's disease, which are the most common types of inflammatory bowel disease. The primary goals were successfully met for both conditions, with high doses achieving the best results seen with any TL1A monoclonal antibody. Sanofi and Teva plan to start phase 3 development for these diseases after discussions with regulatory authorities, highlighting Sanofi's ambition in the field of immunology.
Tolebrutinib has received Breakthrough Therapy designation from the FDA for treating adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This designation is based on encouraging results from the HERCULES study. Tolebrutinib is the first brain-penetrant BTK inhibitor in multiple sclerosis to achieve this status.
FAQ
- What is the primary business of Sanofi?
- What is the ticker symbol for Sanofi?
- Does Sanofi pay dividends?
- What sector is Sanofi in?
- What industry is Sanofi in?
- What country is Sanofi based in?
- When did Sanofi go public?
- Is Sanofi in the S&P 500?
- Is Sanofi in the NASDAQ 100?
- Is Sanofi in the Dow Jones?
- When was Sanofi's last earnings report?
- When does Sanofi report earnings?